MADISON, Wis., April 25, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the company is showcasing advances in hardware and software designed to improve the cancer treatment experience, at ESTRO 2024. The latest generation CyberKnife® and Radixact® platforms provide medical care teams with the technology necessary for expanding the curative power of radiation therapy and delivering on the focus of this year's congress, bridging the care gap. The European Society for Radiotherapy and Oncology's (ESTRO) annual meeting will take place May 3 to May 7, 2024, in Glasgow, Scotland.
"This year's ESTRO meeting is particularly meaningful as we recognize – and celebrate – 30 years of collaborating with healthcare professionals and industry partners to develop ground-breaking technologies that expand the application of radiation therapy and access to patients who may benefit from care. The precision and accuracy of the CyberKnife and Radixact Systems enable our customers to personalize the way cancer is managed for each patient throughout their treatment journey while also treating more patients, better and faster, than ever before," said Suzanne Winter, Winter, president and CEO of Accuray.
Accuray is a wellness focused organization, taking into account the patient's health and well-being throughout their treatment when prioritizing product enhancements. The solutions featured at ESTRO represent a few of the most recent innovations introduced over a 30 year history of invention and disruption that has led to new standards in care for the radiation therapy industry. Visit Accuray at booth #480 to learn more.
"Accuray takes pride in our legacy of breakthroughs in cancer and neuro-radiosurgical technology. The CyberKnife System was the first platform to integrate robotic mobility with real-time imaging to address tumor motion, allowing unparalleled precision without the requirement of uncomfortable stereotactic frames," said Seth Blacksburg, M.D., MBA, Chief Medical Officer at Accuray. "With the TomoTherapy System—the precursor to the Radixact System—we furthered our impact by being the first to merge computed tomography (CT) with intensity-modulated radiation therapy (IMRT) within one system, enabling clinicians to deliver targeted helical radiation therapy designed to meticulously match the tumor's complex shape."
Continued Dr. Blacksburg, "These innovations enable medical care teams worldwide to confidently and non-invasively treat a wide assortment of malignant and benign disease while minimizing the effect on healthy tissues. Our collaboration with world class physicians and engineers continues to forge improvements in oncology and neuro-radiosurgery, empowering the development of novel solutions that advance—and personalize—patient care."
